Background
==========

The nuclear DNA of eukaryotic cells is organised as chromatin in association with proteins. The basal structural organisation unit of chromatin is the nucleosome consisting of the nucleosome core particle, linker DNA and histone H1. The nucleosome core particle is composed of two molecules of each of the four core histones which form an octamer around which DNA with a length of 146 base pairs is wrapped. These nucleosome cores are connected by linker DNA of variable length. H1 histones are positioned at the linker DNA between the nucleosome cores and therefore they are also called linker histones \[[@B1],[@B2]\]. To date, eleven H1 homologous proteins have been described in humans, including the ubiquitously expressed subtype H1x \[[@B3]\]. Comparison of the biochemical behaviour of H1x with other H1 subtypes revealed similarities but also showed characteristic variations \[[@B4]\]. The regulation of the *H1x*gene expression differs from that of the replication-dependent main class subtypes, but also from that of the replacement subtype H1.0. Interestingly, the activity of H1x seems to be controlled not only on level of expression, but also by a cell-cycle-dependent change of its intranuclear distribution \[[@B5]\].

H1 histones actively regulate chromatin processes such as gene expression \[[@B6]\], DNA replication \[[@B7]\] and repair \[[@B8]\]. Aberrations in such epigenetic mechanisms can be associated with malignant transformation \[[@B9],[@B10]\]. Since histone H1 modulates both chromatin structure and transcriptional activity, it is conceivable that H1 histones may contribute to epigenetic phenomena leading to malignant transformation. Change of the H1 subtype composition during tumourigenesis has been described in several studies \[[@B11]-[@B13]\]. A greater number of these reports deals with the replacement H1 subtype H1.0. Some of these data showed an increase of H1.0, others demonstrated a decrease in comparison to the paired normal tissue \[[@B14],[@B15]\]. During our studies on characteristics of the H1 subtype H1x, a Blast data base search revealed an accumulation of expressed sequence tags (ESTs) of H1x in libraries from neuroendocrine tumours (NETs). NETs are a very heterogenous group of rare epithelial tumours that originate from neuroendocrine cells and mostly occur in the gastrointestinal tract and in the lung \[[@B16]-[@B18]\]. In the present study we investigated the occurrence of H1x in cells of NET tissues using immunohistochemistry and compared the expression of H1x in NETs with that in paired normal tissue on protein and on mRNA level using Western blot analysis and quantitative real-time RT-PCR, respectively. Furthermore, double labelling of H1x and chromogranin A, a marker for neuroendocrine cells, of sections from normal tissue of pancreas and small intestine revealed that H1x is highly expressed in neuroendocrine cells of these tissues.

Methods
=======

Bioinformatics
--------------

Data base searches were carried out with the Blast program <http://blast.ncbi.nlm.nih.gov/Blast.cgi>.

Tumour samples
--------------

Snap-frozen as well as formalin-fixed and paraffin-embedded tumour samples from 13 primary NETs and from 1 liver metastasis of a NET were recruited. Paired non-neoplastic tissues of 8 tissue samples were used as control (Table [1](#T1){ref-type="table"}). Pathohistological examination was performed using haematoxylin-eosin-stained sections of each specimen. The study was performed according to the ethical guidelines of the Declaration of Helsinki and was approved by the local ethics committee (no. 32/12/05).

###### 

Tumour samples from neuroendocrine tumours (NETs) and paired non-neoplastic tissue samples used in the present study.

  **Patient no**.   **Sample no**.   **Organ**         **Tissue**       **Subtype**
  ----------------- ---------------- ----------------- ---------------- ---------------------------------------------------------------
  1                 1                lung              non-neoplastic   
                                                                        
  1                 2                lung              NET              Carcinoid
                                                                        
  2                 3                lung              non-neoplastic   
                                                                        
  2                 4                lung              NET              poorly differentiated small cell carcinoma
                                                                        
  3                 5                lung              non-neoplastic   
                                                                        
  3                 6                lung              NET              carcinoid
                                                                        
  4                 7                lung              NET              poorly differentiated small cell carcinoma
                                                                        
  5                 8                small intestine   non-neoplastic   
                                                                        
  6                 9                small intestine   non-neoplastic   
                                                                        
  7                 10               small intestine   NET              well-differentiated carcinoma
                                                                        
  8                 11               small intestine   NET              poorly differentiated small cell carcinoma
                                                                        
  9                 12               small intestine   NET              well-differentiated carcinoma
                                                                        
  10                13               small intestine   NET              carcinoid
                                                                        
  11                14               small intestine   NET              carcinoid
                                                                        
  12                15               pancreas          non-neoplastic   
                                                                        
  13                16               pancreas          non-neoplastic   
                                                                        
  13                17               pancreas          NET              well-differentiated carcinoma
                                                                        
  14                18               pancreas          NET              poorly differentiated large cell carcinoma
                                                                        
  15                19               pancreas          NET              well-differentiated carcinoma
                                                                        
  16                20               pancreas          NET              well-differentiated carcinoma
                                                                        
  17                21               liver             non-neoplastic   
                                                                        
  17                22               liver             NET              liver metastasis of well-differentiated carcinoma of pancreas

Immunohistochemistry
--------------------

For immunohistochemical analysis, tissue microarrays (TMAs) were constructed using a semi-automated manual tissue arrayer (Alphametrix, Rodgau, Germany) to conduct tissue punches with a diameter of 1 mm. For each of the samples, 6 tissue punches from different areas were analysed. The 1 μm thick sections were mounted on sialanised slides, dewaxed, rehydrated and antigen-retrieved in 10 mM citrate buffer (pH 6.0) for 45 min in a pressure cooker. The following steps were carried out using the Dako Cytomation ChemMate Detection Kit (Dako, Glostrup, Denmark) according to the manufacturer\'s description. The sections were probed with affinity-purified anti-H1x antibody at a final concentration of 1.5 μg/ml \[[@B5]\] or anti-chromogranin A antibody (DAK-A3, Dako, Glostrup, Denmark) in a 1:150 dilution. The slides were counterstained with aniline blue and mounted in xylol.

Double-labelling experiments
----------------------------

Sections from formalin-fixed and paraffin wax-embedded samples were deparaffinised in xylol, rehydrated, and washed in Tris buffered saline (TBS; 50 mM Tris, pH 7.5, 152 mM NaCl). Antigen-retrieval was done by incubation in 10 mM citrate buffer (pH 6.0) for 45 min at 95°C. Sections were permeabilised with 0.3% Triton X-100 in TBS for 45 min and blocked by incubation with 3% BSA in TBS containing 0.05% Tween-20 (TBS-T). Sections were then incubated with the following primary antibodies: Affinity-purified anti-H1x antibody at a final concentration of 1.5 μg/ml \[[@B5]\] or anti-chromogranin A antibody (DAK-A3, Dako, Glostrup, Denmark) in a 1:150 dilution. After washes in TBS (3 × 5 min), sections were incubated with the following secondary antibodies in a 1:1000 dilution: Alexa-Fluor 555-anti-mouse IgG (\#21425), Alexa Fluor 488-anti-rabbit IgG (\#11070) from Molecular Probes. Thereafter, sections were rinsed in TBS (3 × 5 min), dehydrated and cleared in xylol. The nuclei were visualised with the fluorochrome 4\'-6-diamidine-2-phenyl indole (DAPI) using Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, USA). For fluorescence microscopy an Axioskop (Zeiss, Göttingen, Germany) was used.

Histone extraction
------------------

Purification of whole histones from snap-frozen tissue samples was done using sulfuric acid. 100 mg tissue was homogenised in 1 ml PBS, containing protease inhibitors (Complete, Roche Diagnostics, Mannheim, Germany) using an ultra turrax. Sulfuric acid was added (final concentration 0.2 M) to the homogenate, and histone extraction was done by incubation for one hour on ice. Samples were centrifuged (10 min, 4°C, 14,000 × g) and the acid-soluble proteins in the supernatant were precipitated with a final concentration of 20% TCA (w/v) for one hour. After centrifugation (30 min, 4°C, 14,000 × g), the pellet was washed with cold (-20°C) acetone and air-dried. The histones were dissolved in 30 mM HCl.

Immunoblotting
--------------

Histones were separated on 15% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose. Uniform blotting was checked by staining the nitrocellulose filter with Ponceau S (Sigma, Taufkirchen, Germany). Blots were probed with polyclonal H1x-specific antiserum in a 1:5000 dilution \[[@B4]\], anti-H1.2 antibody (\#ab17677, Abcam, Cambridge, UK) in a 1:1000 dilution or a mouse monoclonal anti-H1.0 antibody (kindly provided by Prof. H. Zentgraf, German Cancer Research Center, Heidelberg, Germany) in a 1:160 dilution. The immunoreactive proteins were visualized using the chemiluminescence ECL plus detection system (Amersham Bioscience, Freiburg, Germany) after incubation with a horseradish peroxidase-conjugated goat anti-rabbit antibody (\#A0545, Sigma, Taufkirchen, Germany) or horseradish peroxidase-conjugated goat anti-mouse antibody (\#A9917, Sigma, Taufkirchen, Germany). Stripping of blotting membranes for reprobing was done by incubation of the membranes in stripping buffer (100 mM 2-Mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) for 30 min at 50°C with occasional agitation. Bands on the ECL film were quantified with the 1Dscan Ex gel analysis software (Scanalytics, Rockville, USA). The ratios of H1x and H1.0 to H1.2 were calculated, and the mean values of the non-neoplastic tissues were set to 1 to show the fold-change difference of the protein amounts in the NETs.

Quantitative real-time RT-PCR
-----------------------------

Total RNA was extracted from snap-frozen tissue material with TRIzol reagent (Invitrogen Life Technologies, Mannheim, Germany) according to the manufacturer\'s manual and dissolved in RNase-free water. Total RNA concentration was quantified with the RNA 6000 nano LabChip using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA). Superscript II RNase H- Reverse Transcriptase (Invitrogen Life Technologies) was used to generate first strand cDNA from 5 μg RNA per sample according to the manual. 125 ng of random hexamer primers (Invitrogen Life Technologies) and 40 U of RNasIn ribonuclease inhibitor (Promega, Mannheim, Germany) were applied per sample. H1 subtype expression was analyzed with quantitative real-time RT-PCR using gene-specific primers (H1x, primer A, CCCAACGATGTAGCGTTTTT, primer B, AAGGCCGAGAGCCAATAGA, amplicon length, 80 bp; H1.2, primer A, GCCACTTGTACCCGAGTTTT, primer B, TTCTTCTTTACAGGGGCCTTC, amplicon length, 99 bp). Triplicate PCRs were run in an iCycler (Bio-Rad Laboratories GmbH, München, Germany) using the Eurogentec qPCR Core kit for SYBR Green I No ROX (Eurogentec, Seraing, Belgium) and gene-specific primers in a final concentration of 300 nmol/l. The temperature profile consisted of (i) an initial step at 95°C for 10 min; (ii) 40 cycles at 95°C for 15 s and 60°C for 60 s; and (iii) a final melting curve analysis with a temperature ramp from 60 to 95°C and a heating rate of 3°C/min. PCR efficiencies were calculated with a relative standard curve derived from a cDNA mixture (a twofold dilution series with seven measuring points in triplicates) and gave regression coefficients \>0.95 and reproducible primer-specific efficiencies of 84--99%. Gene-specific amplification was confirmed by a single peak in melting curve analysis and a single band in agarose gel electrophoresis. No template controls (no cDNA in PCR) and genomic controls (no enzyme in reverse transcription) were run for each gene to detect unspecific and genomic amplification or primer dimerisation. Gene expression levels were determined by relative quantification using the expression of histone *H1.2*for normalization. To compare the Ct-values of the qRT-PCR results from different samples, the 2^-(ΔΔCt)^method described by \[[@B19]\] was applied. Statistics, Wilcoxon test and graphs were performed with Statistica 6.0 (StatSoft, Hamburg, Germany).

Results and discussion
======================

Immunohistochemical detection of H1x in NETs
--------------------------------------------

A Blast data base search revealed a strikingly high portion of EST entries of the H1 subtype H1x from the libraries LU24 and LU5 (225 entries of 500 displayed with an E value of 0.0) which both originated from tissues of neuroendocrine lung carcinoids (Cancer Genome Anatomy Project \[[@B20]\]). In comparison, searches with the sequences of H1.0 and H1.2 showed no clustering of EST entries in any library (data not shown). As a consequence of this result we decided to investigate the occurrence of H1x in NETs from the lung and the gastrointestinal tract by immunohistochemistry. Sections of poorly differentiated neuroendocrine carcinomas of lung and small intestine as well as of well-differentiated neuroendocrine carcinoma of pancreas were used (Table [1](#T1){ref-type="table"}). Staining of these sections with affinity-purified H1x-antibody resulted in an intensive and uniform immunoreaction of the tumour cells (Figure [1](#F1){ref-type="fig"}). This result demonstrates that H1x is indeed highly expressed in NETs.

![**Immunohistochemical detection of histone H1x in sections from NET tissues**. The three different NETs were (A) poorly differentiated carcinoma of lung (Table [1](#T1){ref-type="table"}, sample no. 4), (B) well-differentiated pancreatic carcinoma (sample no. 19) and (C) poorly differentiated carcinoma of small intestine (sample no. 11). The tumour cells showed an intensive immunoreaction with the anti-H1x antibody. Scale bar = 100 μm.](1471-2407-8-388-1){#F1}

Quantitative analysis
---------------------

Since the immunohistochemical results showed a high expression of H1x in neuroendocrine tumour cells we next performed a quantitative analysis of the H1x expression on mRNA and on protein level in NET tissues compared with that in the corresponding normal tissue. Since several reports described a change of the expression level of the H1 replacement subtype H1.0 during tumourigenesis, the relative expression levels of this subtype was also determined.

The determination of the relative protein amounts of H1x and H1.0 was done by immunoblotting. Histones were extracted by acid extraction from snap-frozen tumour material of neuroendocrine tumours and of the corresponding normal tissue. About equal amounts of H1 histones were loaded, as monitored by detection of the subtype H1.2 which is considered as one of the basal H1 subtypes detected in all cell types investigated so far \[[@B21],[@B22]\]. In tissues from lung and small intestine a strikingly higher protein level of H1x was observed in the tumour tissues compared to the non-neoplastic tissues (Figures [2A/B](#F2){ref-type="fig"}, lung, small intestine). Regarding the pancreas, one of the non-neoplastic tissues showed a relatively high protein level of H1x whereas in the second sample from normal tissue the amount of H1x was very low (Figure [2A](#F2){ref-type="fig"}, lanes 15 and 16). Even in a liver metastasis of a pancreatic well-differentiated carcinoma, the level of H1x was higher than in non-neoplastic liver tissue (Figure [2A](#F2){ref-type="fig"}, lanes 22 and 23). In conclusion the H1x level was higher in the NET tissues than in the normal tissues (Figure [2B](#F2){ref-type="fig"}). In contrast, no increase in H1.0 protein level in NETs compared to non-neoplastic tissues was observed (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}, H1.0). The amount of H1.0 in the NET tissues was partially lower (e.g. Figure [2A](#F2){ref-type="fig"}, lanes 2 and 3) and partially higher (e.g. Figure [2A](#F2){ref-type="fig"}, lanes 5 and 14) than in the corresponding normal tissues. This observation fits the result of earlier studies which either found an increase or a decrease of H1.0 in tumour tissues in comparison to the paired normal tissues (reviewed in \[[@B14]\]).

![**(A) Relative protein amounts of the H1 histone subtypes H1x, H1.2 and H1.0 in non-neoplastic and neuroendocrine tumour tissues**. Determination of relative protein levels of histone H1x, main type subtype H1.2 and replacement histone H1.0 was done by Western blot analysis. Lane 1, normal tissue of lung (Table [1](#T1){ref-type="table"}, sample no. 3), lane 2, neuroendocrine carcinoid of lung (no. 2), lane 3, poorly differentiated neuroendocrine small cell carcinoma of lung (no. 4), lane 4, normal tissue of lung (no. 5), lane 5, neuroendocrine carcinoid of lung (no. 6), lane 6, poorly differentiated small cell carcinoma of lung (no. 7), and lanes 7 and 8, normal tissue of small intestine (no. 8 and 9), lane 9, well-differentiated neuroendocrine carcinoma of small intestine (no. 10), lane 10, poorly differentiated neuroendocrine carcinoma (no. 11), and lane 11 well-differentiated neuroendocrine carcinoma of small intestine (no. 12), lane 12, normal tissue of small intestine (no. 8), lanes 13 and 14, neuroendocrine carcinoid of small intestine (no. 13 and 14), lane 15 and 16, normal tissue of pancreas (no. 15 and 16), lane 17, pancreatic neuroendocrine tumour of poor differentiation (no. 18) and lane 18, of good differentiation (no. 19), lane 19, normal tissue of pancreas (no. 16), lanes 20 and 21, well-differentiated carcinoma of pancreas (no. 17 and 20), lane 22, normal tissue of liver and lane 23, liver metastasis of well-differentiated carcinoma of pancreas (no. 21 and 22). (B) Densitometric quantitation of the immunoblots shown in (A). Ratios of H1x and H1.0 to H1.2 were calculated and standard deviations are indicated.](1471-2407-8-388-2){#F2}

The mRNA level of H1x, H1.2 and H1.0 in NET tissues and non-neoplastic tissues was analysed by quantitative real-time RT-PCR. The ratios of H1x and H1.0 to the main-class subtype H1.2 were calculated (Figure [3](#F3){ref-type="fig"}). A significantly higher expression of H1x in the NETs of lung and small intestine compared to the non-neoplastic tissues was found. However, in the tissue samples of pancreas no difference in the H1x expression but a decrease of the H1.0 expression was observed. Since high protein amounts of H1x have been determined in the NETs of pancreas by immunohistochemistry and Western blot analysis, this result may be explained by a differential protein turnover or varied kinetics of transcription and translation like is has been described for the subtype H1.0 \[[@B23]\].

![**Box plot presentation of the relative RNA levels of H1x and H1.0 determined by quantitative real-time RT-PCR**. Total RNA was extracted from normal lung tissues (Table [1](#T1){ref-type="table"}, samples no. 1 and 3), NETs from lung (no. 2 and 4), normal tissues from small intestine (no. 8 and 9), NETs from small intestine (no. 10, 11 and 12), normal tissue from pancreas (no. 15) and pancreatic NETs (no. 17, 18 and 19) and used for reverse transcription. The generated cDNA from each patient was used for triplicate quantitative real-time PCR. Gene expression levels of *H1x*and *H1.0*were determined by relative quantification using the expression of histone *H1.2*for normalization. Wilcoxon test was used for statistical analysis. The mRNA level of H1x was significantly increased in NET tissue of lung (*p*= 0.004) and small intestine (*p*= 0.01). Horizontal line, median; inner box, 25 and 75% interval; outer spread, minimum and maximum.](1471-2407-8-388-3){#F3}

In summary, although the sample size of the present study was relatively low, these results clearly show an increased expression of the H1 histone subtype H1x in the analysed group of NETs compared to the corresponding normal tissues.

Detection of H1x in neuroendocrine cells
----------------------------------------

The finding that H1x is highly expressed in neuroendocrine tumour cells raised the question whether H1x is generally abundant in neuroendocrine cells. To answer this question, indirect immunofluorescence double-labelling of H1x and chromogranin A was performed. Chromogranin A, a marker protein for neuroendocrine cells, is a secretory granin protein that is co-stored and co-released with peptides and amines. It seems to be crucial for the formation of secretory granules and sequestration of hormones in neuroendocrine cells \[[@B24]-[@B26]\]. In pancreatic tissue, scattered chromogranin A-positive cells show a high protein amount of histone H1x compared to the surrounding chromogranin A-negative cells (Figure [4A](#F4){ref-type="fig"}). Interestingly, endocrine cells of islets of Langerhans also exhibit a relatively high expression of H1x (Figure [4B](#F4){ref-type="fig"}). Double-labelling of sections of small intestine revealed that the chromogranin A-positive neuroendocrine cells contain higher levels of H1x than the surrounding cells of the glandulae intestinales (Figure [4C](#F4){ref-type="fig"}). However, an abundance of H1x was also observed in some cells of the stroma of the villi. Unfortunalely, analysis of lung tissue with immunofluorescence labelling was not possible, since lung sections display a very strong autofluorescence which is mainly caused by elastin fibers \[[@B27],[@B28]\].

![**Indirect immunofluorescence detection of H1x and chromogranin A in sections of paraffin wax-embedded samples from pancreas and small intestine**. Chromogranin A (CgA) was used as a marker protein for neuroendocrine cells which show scattered location in these tissues. (A) Chromogranin A-positive cells in pancreatic tissue exhibit a relatively high expression of H1x. Scale bar = 10 μm. (B) Cells of a islet of Langerhans show a strong immunoreaction with the anti-H1x antibody. Scale bar = 20 μm. (C) H1x is abundant in chromogranin A-positive cells of small intestine (arrows) compared to the surrounding cells of the glandulae intestinales and also in some cells of the stroma of the villi (arrowheads). Scale bar = 20 μm.](1471-2407-8-388-4){#F4}

Conclusion
==========

The results of this study clearly show that the H1 subtype H1x is considerably expressed in neuroendocrine cells of pancreas and small intestine, and also in endocrine cells of islets of Langerhans. Thus, the high expression of histone H1x in NETs is probably due to the high expression of this protein in the cells from which these tumours originated. Further research into molecular mechanisms by which H1x exerts its function is needed to find out whether this increased expression is linked to the endocrine function of these cells and/or whether this H1 subtype participates in the tumourigenesis of NETs.
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